Evidence map›Paper›PMID 33627652›Full record

ArticleNature communications2021

The neutrophil antimicrobial peptide cathelicidin promotes Th17 differentiation.

Danielle Minns, Katie J Smith, Virginia Alessandrini, Gareth Hardisty, Lauren Melrose, Lucy Jackson-Jones, Andrew S MacDonald, Donald J Davidson, Emily Gwyer Findlay

Open access · goldAbstract read
In one paragraph

Article in Nature communications, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 96 papers.

0numbers the graph read from it
0cells of the map it votes in
96citing papers in PubMed
8.2field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

96 citing papers in PubMed, 136 citations in OpenAlex.

  1. Trial
  2. Article
  3. Article
  4. Impact of cathelicidin cleavage by SpeB onbioRxiv : the preprint server for biology · 2026
    Article
  5. Review
  6. Article
  7. Article
  8. Article
  9. Article
  10. Rosacea scleritis and sclero-uveitis; under recognised and over treated.Journal of ophthalmic inflammation and infection · 2026
    Review
  11. Article
  12. Review
  13. Neutrophil-T cell cross talk in noninfectious liver diseases.American journal of physiology. Gastrointestinal and liver physiology · 2026
    Review
  14. Extended-Spectrum β-Lactamase-ProducingAntibiotics (Basel, Switzerland) · 2025
    Review
  15. Article
  16. Article
  17. Review
  18. Review
  19. Article
  20. Article

36 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 3 institutions in 1 country.

Danielle MinnsCentre for Inflammation Research, University of Edinburgh; 47 Little France Crescent, Edinburgh, UK.
Katie J SmithCentre for Inflammation Research, University of Edinburgh; 47 Little France Crescent, Edinburgh, UK.
Virginia AlessandriniCentre for Inflammation Research, University of Edinburgh; 47 Little France Crescent, Edinburgh, UK.
Gareth HardistyCentre for Inflammation Research, University of Edinburgh; 47 Little France Crescent, Edinburgh, UK.
Lauren MelroseCentre for Inflammation Research, University of Edinburgh; 47 Little France Crescent, Edinburgh, UK.
Lucy Jackson-JonesDivision of Biomedical and Life Sciences, Lancaster University, Lancaster, UK.
Andrew S MacDonaldLydia Becker Institute of Immunology and Inflammation, University of Manchester, Oxford Road, Manchester, UK.ORCID http://orcid.org/0000-0002-5356-1149
Donald J DavidsonCentre for Inflammation Research, University of Edinburgh; 47 Little France Crescent, Edinburgh, UK.ORCID http://orcid.org/0000-0002-8782-199X
Emily Gwyer FindlayCentre for Inflammation Research, University of Edinburgh; 47 Little France Crescent, Edinburgh, UK. Emily.findlay@ed.ac.uk.ORCID http://orcid.org/0000-0002-2311-6589
Centre for Inflammation Research · GBLancaster University · GBUniversity of Manchester · GB

Funding

Medical Research Council G1002046
6 · The paper itself

Abstract

The host defence peptide cathelicidin (LL-37 in humans, mCRAMP in mice) is released from neutrophils by de-granulation, NETosis and necrotic death; it has potent anti-pathogen activity as well as being a broad immunomodulator. Here we report that cathelicidin is a powerful Th17 potentiator which enhances aryl hydrocarbon receptor (AHR) and RORγt expression, in a TGF-β1-dependent manner. In the presence of TGF-β1, cathelicidin enhanced SMAD2/3 and STAT3 phosphorylation, and profoundly suppressed IL-2 and T-bet, directing T cells away from Th1 and into a Th17 phenotype. Strikingly, Th17, but not Th1, cells were protected from apoptosis by cathelicidin. We show that cathelicidin is released by neutrophils in mouse lymph nodes and that cathelicidin-deficient mice display suppressed Th17 responses during inflammation, but not at steady state. We propose that the neutrophil cathelicidin is required for maximal Th17 differentiation, and that this is one method by which early neutrophilia directs subsequent adaptive immune responses.

Indexed as

AnimalsAntimicrobial Cationic PeptidesCathelicidinsCell DifferentiationCells, CulturedEnzyme-Linked Immunosorbent AssayFemaleFlow CytometryHumansImmunohistochemistryMaleMiceMice, Inbred C57BLNeutrophilsPhosphorylationPore Forming Cytotoxic ProteinsAntimicrobial Cationic PeptidesCathelicidinsPore Forming Cytotoxic ProteinsSmad2 ProteinSmad2 protein, mouseSmad3 ProteinSmad3 protein, mouseStat3 protein, mouseSTAT3 Transcription Factor

Identifiers

PMID33627652
PMCPMC7904761
OpenAlexW3132361143

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.